The NHS has announced it will offer a new therapy to treat children with a rare and painful skin condition known as 'jack ladybird' or epidermolysis bullosa (EB). The condition causes the skin to blister and tear at the slightest touch, leading to severe pain and risk of infection.
New Treatment Approved
Following a successful clinical trial, the National Institute for Health and Care Excellence (NICE) has approved the use of a gene therapy called beremagene geperpavec (B-VEC) for children with dystrophic epidermolysis bullosa. The treatment, which is applied as a gel to wounds, works by delivering a working copy of the gene responsible for producing collagen, which is missing in patients with the condition.
According to NHS England, around 100 children in England are expected to benefit from the therapy, which will be available at specialist centres in London, Birmingham, and Manchester. The treatment has been shown to significantly reduce pain and improve wound healing in clinical trials.
Patient and Expert Reactions
James Murray, a consultant dermatologist at the Royal London Hospital, said: "This is a life-changing development for children with epidermolysis bullosa. The therapy not only helps heal wounds but also reduces the constant pain these children endure."
One parent of a child with the condition described the news as "a dream come true," adding that their child has suffered from severe blistering since birth. The therapy is expected to be rolled out within the next few months.
Impact on Children and Families
Epidermolysis bullosa affects approximately 1 in 50,000 children. The condition can lead to severe scarring, difficulty eating, and an increased risk of skin cancer. The new therapy offers hope for improved quality of life, reducing the need for frequent dressing changes and hospital visits.
The NHS has committed to funding the treatment, which costs around £500,000 per patient per year. However, officials say the long-term savings from reduced hospital stays and complications will offset the cost.
